Novartis Payments For Kymriah Treatment Logistics Avoid Kickback Concerns
Executive Summary
US HHS Office of Inspector General clears company program to provide travel expenses and lodging to needy patients located far from designated treatment centers.
You may also be interested in...
Novartis CAR-T Patient Assistance Program Could Set Template For Other One-Time Treatments
HHS gives kickback exemption for program to provide Kymriah for free to certain eligible patients regardless of insurance provider. Treatment’s one-time use as a last resort therapy were key to the US government’s advisory opinion reasoning.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.